The Controlled Release Alliance (Between Colorcon, Inc. and Dow Wolff Cellulosics) Introduces Methocel™ DC Premium Grade Excipient for Direct Compression of Controlled Release...
Dow Wolff Cellulosics, a business unit of The Dow Chemical Company, along with their Controlled Release Alliance partner, Colorcon Inc., today announced the launch of METHOCELâ?¢ Direct Compression (DC) Premium Grade Hypromellose Polymers, a new product that can reduce the costs of manufacturing matrix tablets by eliminating the wet granulation process. Specifically designed for direct compression, METHOCEL DC Premium Grade provides improved powder flow over standard Hypromellose grades, while maintaining key drug formulation attributes, such as tablet hardness and controlled release drug performance.
Studies have shown that METHOCEL DC Grade polymers consistently deliver optimal flow, processing and tablet properties, and eliminate the need for additional flow-enhancing ingredients. In addition, direct compression is a simpler process that can shorten product development timelines, minimize necessary manufacturing controls, and can be useful for heat and moisture sensitive active pharmaceutical ingredients.
"Direct compression is becoming the preferred option for tablet manufacturing as pharmaceutical companies look to offer more controlled release options to patients," said Lucrece Foufopoulos, Global Marketing Director, Dow Wolff Cellulosics. "With METHOCEL DC Premium Grade, we can now meet this need for our customers, while delivering cost savings and better performance."
"Helping formulators to achieve more, in less time, is a cornerstone of the Controlled Release Alliance," said David Bain, General Manager, Formulation Technologies, Colorcon. "METHOCEL DC Premium Grade opens up direct compression as a viable manufacturing option to a wider range of drugs, doses and customers, who can rely on Colorcon global network of application expertise to help realize these benefits."
METHOCEL Premium DC Grade Hypromellose Polymers provide optimal value when designing drug formulations specifically for direct compression processing. They can replace conventional polymers when the goal is to improve processing and dosage properties. There are two direct compression grades currently available: METHOCEL K4M Premium DC and METHOCEL K100M Premium DC. Both will be exclusively supported and distributed through the Colorcon and Dow Wolff Cellulosics Controlled Release Alliance.
About Dow Wolff Cellulosics
Dow Wolff Cellulosics is a global leader and pioneer in Cellulose Ethers and preferred development partner for manufacturers and suppliers in the food and pharmaceutical markets, and in other industrial specialty applications. It supplies high-performance, cellulose-based products and formulation know-how to help customers innovate and differentiate in highly-regulated markets.
Cellulosics and their derivatives are produced from renewable raw materials, mainly wood pulp and cotton, sourced primarily from suppliers that implement certified sustainable forestry practices. Ranging from healthier food ingredients and formulations, to enhanced pharmaceutical delivery, most products containing Cellulosics help to make improvements in the daily lives of billions of people.
Dow Wolff Cellulosics is a business unit of The Dow Chemical Company, employing 1,200 people across more than nine sites and 15 assets, with six cGMP's, serving customers in around 160 countries.
More details can be found at www.dowwolffcellulosics.com.
Colorcon is a world leader in the development, supply and technical support of formulated film coating systems, modified release technologies, and functional excipients for the pharmaceutical industry. Our best-in-class products and technologies are complemented by our value-added services, which support all phases of solid oral dose design and development. Colorcon has sole global and exclusive sales and distribution rights for Dow Wolff Cellulosics' products used in controlled release applications through the Controlled Release Alliance.